Expertise in
11
conditions

Dr. Dana B. Cardin

Gastroenterology
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 

Overview

Dana Cardin is a Gastroenterologist practicing medicine in Nashville, Tennessee.

Dr. Cardin is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, and Colorectal Cancer.

She is actively involved in clinical research, co-authoring 45 peer reviewed articles and participating in 16 clinical trials. Dr. Cardin is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in TN

Hospital Affiliations

Vanderbilt Wilson County Hospital
Vanderbilt University Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 21, 2026
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug, Procedure
Study Drugs: Cediranib Maleate, Olaparib
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 20, 2026
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma
A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Dasatinib, Erlotinib, Gemcitabine
Study Phase: Phase 1
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Enrollment Status: Terminated
Publish Date: November 06, 2024
Intervention Type: Drug
Study Drugs: SM-88, MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, 5-FU
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: April 25, 2023
Intervention Type: Drug
Study Drugs: Adavosertib, Gemcitabine hydrochloride, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
View 9 Less Clinical Trials

45 Total Publications

Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma.
Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma.
Journal: European radiology
Published: February 21, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Michael F. Vaezi
Gastroenterology
Expertise in
14
conditions
Dr. Michael F. Vaezi
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-7427
Languages Spoken:
English, Farsi, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Vaezi is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Vaezi is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Esophagitis, Achalasia, Heartburn, and Endoscopy. Dr. Vaezi is currently accepting new patients.

Expertise in
9
conditions
Dr. David M. Schwartz
Gastroenterology
Expertise in
9
conditions
Dr. David M. Schwartz
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-0128
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Schwartz is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Schwartz is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Pulmonary Fibrosis, Endoscopy, and Colonoscopy. Dr. Schwartz is currently accepting new patients.

Expertise in
18
conditions
Dr. Patrick S. Yachimski
Gastroenterology
Expertise in
18
conditions
Dr. Patrick S. Yachimski
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-0128
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Yachimski is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Yachimski is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Barrett Esophagus, Pancreatic Pseudocyst, Neuroma Biliary Tract, Endoscopy, and Pancreatectomy. Dr. Yachimski is currently accepting new patients.

Frequently Asked Questions about Dr. Dana B. Cardin

How do I make an appointment with Dr. Dana B. Cardin?

You can book an appointment with Dr. Dana B. Cardin by calling their office at 615-322-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dana B. Cardin a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dana B. Cardin is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dana B. Cardin specialize in?

While Dr. Dana B. Cardin is a Gastroenterology, they have specific expertise in Pancreatic Cancer, Familial Pancreatic Cancer, and Neuroendocrine Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Dana B. Cardin participate in research or clinical trials?

Yes. Dr. Dana B. Cardin has published 45 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Dana B. Cardin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dana B. Cardin accept my insurance?

Dr. Dana B. Cardin accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 615-322-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cardin's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile